Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

IL DONG PHARMACEUTICAL CO., LTD.

일동제약249420KOSPISector: Pharma & Biotech
₩14,5001.83%Market cap ₩458.8BAs of Sep 1, 2026 close · updated once daily
Market cap
₩458.8B
#312 in KOSPI
16.9x
Sector median 16.1x (profitable cos.)
1.90x
Sector median 1.59x
0.5%
Sector median 0.0%
B
Grade B55 ptsTop 44% of 2,523 graded stocksMethodology v2.0
Financial strength
47.9/100
Growth momentum
53.7/100
Price attractiveness
60.3/100
Shareholder Return
78.9/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCurrentCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band B with a total score of 55 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩12,150High ₩44,300
Latest close
Price change by period
1W
1.80%
1M
5.60%
3M
31.20%
1Y
40.60%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

47.9/100
How much debt does it carry relative to equity?
139.2%
Sector median 51.6%
Sector lowhighBottom 14.8% in sector
Can it cover what's due within a year?
96.1%
Sector median 191.7%
Sector lowhighBottom 22.5% in sector
How much of revenue becomes profit?
3.4%
Sector median -2.4%
Sector lowhighTop 36.3% in sector
How much did it earn on its own capital?
11.2%
Sector median -4.5%
Sector lowhighTop 9.5% in sector

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

53.7/100
How much did revenue grow in a year?
-7.8%
Sector median 6.4%
Sector lowhighBottom 22% in sector
Has it grown steadily over three years?
-3.8%
Sector median 4.9%
Sector lowhighBottom 24.5% in sector
Did core profits grow in a year?
48.5%
Sector median 3.6%
Sector lowhighTop 19.8% in sector
Are core profits higher than three years ago?
126.5%
Sector median 3.5%
Sector lowhighTop 12.1% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

60.3/100
Is the price expensive relative to earnings?
16.9x
Sector median P/E of profitable peers 16.1x · 58% loss-making
Sector lowhighTop 22.5% in sector
Is the price expensive relative to book value?
1.90x
Sector median 1.59x
Sector lowhighBottom 43.1% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis78.9/100
Does the company actually pay dividends?
0.5%
Sector median 0.0%
Sector lowhighTop 21.1% in sector

Dividend per share (annual)

Cash dividend per common share as stated in annual reports. ₩0 means no dividend that year.

Dividends & treasury shares

Total cash dividends (FY2025)
₩6.3B
Cash payout ratio, consolidated (FY2025)
22.8%
Treasury shares (FY2025)
130,175 shares (0.4% of shares issued)

Source: annual report (DART) — dividend allocation & total shares

Source filing: annual report (consolidated) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 1, 2026

Of 9 items: 6 met · 3 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩27.7B
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩19B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Met
-0.7% → 4.7%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Not met
₩19B vs ₩27.7B
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
73.0% → 58.2%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
89.5% → 96.1%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Not met
28,062,501 → 31,638,252
Operating margin up
Whether operating income over revenue rose from the prior year.
Met
2.1% → 3.4%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
1.01x → 0.96x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (consolidated) — view original ↗

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026BVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Disclosure & financial badges

Factual records determined from public filings and periodic reports by fixed rules — not buy/sell signals.

Negative-evidence group (dilution, loss, dispute)Mixed interpretationPositive-evidence group (shareholder return)Dots classify the disclosure type by the direction of research evidence — not an assessment or investment judgment about this company.

Disclosure event history

CB with conversion-price adjustment clause (past 36 months)

1 convertible bond (CB) issuance resolutions including a downward conversion-price adjustment (refixing) clause were disclosed in the past 36 months (latest filing 2023-10-18). View filing ↗

Determined as of 2026-09-01

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →